EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review

Adam M Kase iD, Abdel-Ghani Azzouqa, Swapna Kochuveettil, Gerardo Colon-Otero

Cancer Medicine · 2023

DOI: 10.1002/cam4.5705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Adam M Kase und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective of this study was to evaluate the efficacy of gemcitabine plus nab‐paclitaxel in patients with recurrent ovarian cancer.

Methods

We performed a single institution retrospective review of patients with recurrent ovarian cancer who were treated with gemcitabine plus nab‐paclitaxel from 2012 to 2018 at the Mayo Clinic in Florida.

Results

Twenty patients were identified and the median PFS for patients treated with gemcitabine plus nab‐paclitaxel was 9 months (95% CI, 5.7–20.7). Overall, 17 of the 20 patients (85%) achieved a clinical benefit (complete response 5%, partial response 55%, or stable disease at 3 months 25%). For platinum‐sensitive disease and platinum‐resistant disease, the median OS were 38.7 months (95% CI, 5.8–63.1) and 31.2 months (95% CI, 12.8–51.8), respectively ( p = 0.4306).

Conclusion

This well‐tolerated regimen shows promising activity in recurrent ovarian cancer and is a viable option for patients who are intolerant to paclitaxel or carboplatin because of allergic reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsNanoparticlesHumansFemaleGemcitabineAlbumin-Bound PaclitaxelRetrospective StudiesDeoxycytidineTreatment OutcomePaclitaxelAlbuminsAntineoplastic Combined Chemotherapy Protocols

Substanzen

Gemcitabine130-nm albumin-bound paclitaxelAlbumin-Bound PaclitaxelDeoxycytidinePaclitaxelAlbumins

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Cancer Care Institute, Monument Health, Rapid City, South Dakota, USA.

ORCID-Profile: Adam M Kase

Förderung

  • NCI NIH HHS

Zitieren

APA

Kase, A. M., Azzouqa, A. G., Kochuveettil, S., & Colon-Otero, G. (2023). Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review. Cancer Medicine. https://doi.org/10.1002/cam4.5705

Vancouver

Kase AM, Azzouqa AG, Kochuveettil S, Colon-Otero G. Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review. Cancer Medicine. 2023. doi:10.1002/cam4.5705

BibTeX
@article{Kase2023,
  author = {Kase, Adam M and Azzouqa, Abdel-Ghani and Kochuveettil, Swapna and Colon-Otero, Gerardo},
  title = {Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5705}
}
Kostenlos starten →